The estimated Net Worth of Martha E Manning is at least $127 mil dollars as of 5 August 2024. Ms. Manning owns over 3,621 units of Marinus Pharmaceuticals Inc stock worth over $83,766 and over the last 9 years she sold MRNS stock worth over $43,015. In addition, she makes $0 as Vice President, General Counsel y Secretary at Marinus Pharmaceuticals Inc.
Martha has made over 4 trades of the Marinus Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently she sold 3,621 units of MRNS stock worth $4,092 on 5 August 2024.
The largest trade she's ever made was selling 3,621 units of Marinus Pharmaceuticals Inc stock on 5 August 2024 worth over $4,092. On average, Martha trades about 637 units every 175 days since 2016. As of 5 August 2024 she still owns at least 60,263 units of Marinus Pharmaceuticals Inc stock.
You can see the complete history of Ms. Manning stock trades at the bottom of the page.
Martha E. Manning serves as Vice President, General Counsel, Secretary of the Company. Ms. Manning has spent over 20 years in the life sciences sector, providing legal advice for development stage and commercial biopharma companies. Immediately prior to joining Marinus, Ms. Manning was Executive Vice President, General Counsel and Secretary for Achillion Pharmaceuticals, Inc., where she helped to develop and execute corporate strategy, managed corporate governance for Board of Directors, and handled all legal and compliance matters. Before her tenure at Achillion, she was General Counsel for ICeutica Inc. where she was also responsible for all legal matters, including supporting corporate growth through R&D, product and clinical development and out licensing, and corporate governance. Ms. Manning has held roles that have included Chief Legal Officer for OraPharma, Inc., Vice President and General Counsel for Sandoz, Inc. (Novartis), Senior Vice President, General Counsel and Secretary for Adolor Corporation, and Business and Finance Associate for the law firm Morgan Lewis & Bockius. Ms. Manning earned her Juris Doctor degree from the University of Pennsylvania Law School and her Bachelor of Business Administration from the University of Massachusetts. She is a member of the Pennsylvania Bar.
Martha Manning is 64, she's been the Vice President, General Counsel y Secretary of Marinus Pharmaceuticals Inc since 2020. There are 2 older and 10 younger executives at Marinus Pharmaceuticals Inc. The oldest executive at Marinus Pharmaceuticals Inc is Martha E. Manning, 66, who is the VP, Gen. Counsel & Sec..
Martha's mailing address filed with the SEC is 5 RADNOR CORPORATE CENTER, SUITE 500, 100 MATSONFORD RD, RADNOR, PA, 19087.
Over the last 10 years, insiders at Marinus Pharmaceuticals Inc have traded over $13,562,679 worth of Marinus Pharmaceuticals Inc stock and bought 2,520,427 units worth $19,488,416 . The most active insiders traders include Nicole Vitullo, Capital Life Sciences Inves... y Anand Mehra. On average, Marinus Pharmaceuticals Inc executives and independent directors trade stock every 68 days with the average trade being worth of $149,293. The most recent stock trade was executed by Christina Shafer on 5 August 2024, trading 3,820 units of MRNS stock currently worth $4,355.
marinus pharmaceuticals is a clinical stage biopharmaceutical company dedicated to positively impacting the well-being of patients who suffer from epilepsy and neuropsychiatric disorders. the company is in the midst of developing and commercializing ganaxolone which will treat adults and children with epileptic seizures and women with postpartum depression. on june 29, 2017, the company announced that the u.s. food and drug administration (fda) granted orphan drug designation to ganaxolone for the treatment of cdkl5 disorder. cdkl5 disorder is a severe, rare genetic disorder that affects children at an early age and causes difficult-to-control seizures and neuro-developmental impairment. currently, there are no approved therapies for children with cdkl5 disorder. orphan drug designation is granted by the fda office of orphan products development to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the u.s. the designation provides
Marinus Pharmaceuticals Inc executives and other stock owners filed with the SEC include: